- Home
- HVT vs EYPT Comparison
HVT vs EYPT Comparison
Compare HVT & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HVT | EYPT |
|---|---|---|
| Founded | 1885 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Laboratory Analytical Instruments |
| Sector | Consumer Discretionary | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 400.9M | 419.9M |
| IPO Year | 1994 | 2005 |
Fundamental Metrics
Financial Performance| Metric | HVT | EYPT |
|---|---|---|
| Price | $27.36 | $4.50 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $31.80 |
| AVG Volume (30 Days) | 132.7K | ★ 5.9M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 6.05% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.77 | N/A |
| Revenue | ★ $758,995,000.00 | $7,539,000.00 |
| Revenue This Year | $8.83 | N/A |
| Revenue Next Year | $8.70 | $3,115.57 |
| P/E Ratio | $35.56 | ★ N/A |
| Revenue Growth | ★ 4.99 | N/A |
| 52 Week Low | $19.90 | $3.95 |
| 52 Week High | $29.83 | $19.11 |
Technical Indicators
Market Signals| Indicator | HVT | EYPT |
|---|---|---|
| Relative Strength Index (RSI) | 56.28 | 28.47 |
| Support Level | $25.26 | $3.95 |
| Resistance Level | $29.83 | $15.17 |
| Average True Range (ATR) | 0.65 | 0.64 |
| MACD | -0.21 | -0.47 |
| Stochastic Oscillator | 40.46 | 5.04 |
Price Performance
Historical ComparisonAbout HVT Haverty Furniture Companies Inc.
Haverty Furniture Companies Inc is a specialty retailer of residential furniture and accessories. It provides various products such as Sofa Tables, Sleepers, End Tables, Cocktail Tables, Accent Pieces, Display Cabinets, Wall Decor, floral and Tress, and other related products. The company operates in the Southern and Midwestern U.S. All its activities are encompassed in its Merchandise division. The company derives the majority of revenue from its upholstery products and, secondarily, from bedroom furniture.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.